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1. Introduction  
Most of the physiological and metabolic processes in any organism are controlled by a 
regulatory factor network, which includes a lot of protein kinases, protein phosphatases and 
transcription factors. Protein kinases and phosphatases are key regulators of the majority of 
transcription factors which control metabolism both in normal and in different pathological 
conditions; it is a circadian type of regulation [1–5]. AMPK-related kinases SNARK and 
NUAK1 as well as many others AMPK-related kinases represent molecular components of 
signalling cascades that control metabolism, gene expression and perhaps cell proliferation 
in response to cellular, metabolic and environmental stresses [6–8].  
The sucrose-non-fermenting protein kinase (SNF1) from Saccharomyces cerevisiae and its 
mammalian counterpart, AMP-activated protein kinase (AMPK), form a family of 
serine/threonine kinases that acts as a master sensor and regulator of the energy balance at 
the cellular level as well as the stress response systems, has been critical to our understanding 
of the whole body energy homeostasis [9]. This family of protein kinases is highly conserved 
between animals, fungi and plants and is commonly activated in response to cellular and 
environmental stresses such as nutrient deprivation. Yeast SNF1 responds to glucose 
deprivation by derepressing genes implicated in carbon source utilization and by 
modulating the transcription of glucose-regulated genes involved in gluconeogenesis, 
respiration, sporulation, thermotolerance, peroxisome biogenesis and cell cycle regulation. 
Activated by environmental stresses AMPK switches off anabolic pathways (e.g. fatty acid 
and cholesterol synthesis) and induces ATP generating catabolic pathways [9]. Twelve protein 
kinases (NUAK1, NUAK2, BRSK1, BRSK2, SIK, QIK, QSK, MARK1, MARK2, MARK3, 
MARK4 and MELK) in the human kinome are closely related to AMPKα1 and AMPKα2, thus 
forming a 14 kinase phylogenetic tree known as “AMPK-related kinases” which represent 
components of signalling cascades that control metabolism, gene expression and perhaps cell 
proliferation in response to cellular, metabolic and environmental stresses [9].  
The AMP-activated protein kinase system acts as a sensor of cellular energy status that is 
conserved in all eukaryotic cells. It is activated by a large variety of cellular stresses that 
increase cellular AMP and decrease ATP levels and also by physiological stimuli, such as 
muscle contraction, or by hormones such as leptin and cellular adiponectin as well as by 
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metabolic stresses that either interferes with ATP production or that accelerate ATP 
consumption [10]. AMPK modulates multiple metabolic pathways. Activation in response to 
an increase in AMP involves phosphorylation by an upstream kinase, the tumour 
suppressor LKB1. Once activated, AMPK switches on catabolic pathways that generate ATP, 
while switching off ATP-consuming processes such as biosynthesis and cell growth and 
proliferation. Thus, it is a key player in the development of new treatments for obesity, the 
metabolic syndrome, type 2 diabetes or even cancer. In fact, it has been recently reported 
that drugs used in the treatment of diabetes, such as metformin and thiazolidinediones, 
exert their beneficial effects through the activation of AMPK. 
The sucrose-non-fermenting protein kinase (SNF1)/AMP-activated protein kinase-related 
kinase (SNF1/AMP-activated protein kinase; SNARK) is a member of AMPK kinases 
(NUAK family SNF1-like kinase 2) which is related to serine/threonine protein kinases [7, 
9]. SNARK activity is regulated by glucose- or glutamine-deprivation, induction of 
endoplasmic reticulum stress by dithyothreitol or homocysteine, elevation of cellular AMP 
and/or depletion of ATP, hyperosmotic stress, salt stress and oxidative stress caused by 
hydrogen peroxide. However, the regulation of SNARK activity in response to cellular 
stresses depends greatly upon cell type. It was also shown that SNARK is also regulated by 
metabolic stress and diabetes [11]. Nuclear localization of SNARK has shown its impact on 
gene expression [12].  
Tsuchihara et al. [13] demonstrated that SNARK(+/-) mice exhibit mature-onset obesity and 
related metabolic disorders. Moreover, the incidence of both adenomas and aberrant crypt 
foci were significantly higher in SNARK(+/-) mice than in their wild-type counterparts, 
suggesting that SNARK deficiency contributed to the early phase of tumourigenesis via 
obesity-dependent and obesity-independent mechanisms [14]. Recently, Namiki et al. [14] 
have shown that AMP kinase-related kinase SNARK affects tumour growth, migration, and 
clinical outcome of human melanoma, further supporting the importance of this protein 
kinase in cancer development and tumour progression, while AMPK has antioncogenic 
properties. We have also shown that the SNF1/AMP-activated protein kinase-related kinase 
is a sensitive marker for the action of ecotoxicant methyl tert-butyl ether (MTBE) as well as 
silver nanoparticles [15, 16]. These observations support a role for SNARK as a molecular 
component of the cellular stress response. 
SNF1-like kinase 1 (NUAK1) is an AMP-activated protein kinase family member 5, ARK5, 
which regulates ploidy and senescence, tumour cell survival, malignancy and invasion 
downstream of Akt signaling, acts as an ATM kinase under the conditions of nutrient 
starvation [17–20]. Moreover, NUAK1 suppresses the apoptosis, induced by nutrient 
starvation, and death receptors via inhibition of caspase-8 and caspase-6 activation [21, 22]. 
Importantly, AMPK-related kinase NUAK1 as well as many others AMPK kinases 
(including MARK/PAR-1) is regulated by protein kinase LKB1 and USP9X [23, 24]. 
2. NUAK family SNF1-like kinase 2 (NUAK2), Sucrose nonfermenting AMPK-
related kinase (SNARK)  
Human NUAK family SNF1-like kinase 2 (NUAK2; EC_number "2.7.11.1") also known as 
sucrose nonfermenting AMPK-related kinase or skeletal muscle sucrose, nonfermenting 
1/adenosine monophosphate activated protein kinase-related kinase (SNARK) is an AMP-
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activated protein kinase family member 4, which was identified 10 years ago as an potential 
mediator of cellular response to metabolic stress [9].  
2.1 NUAK2 gene, transcripts and encoded proteins 
The human NUAK2 (SNARK) gene (geneID: 81788) is localized on chromosome 1 (1q32,1). 
The SNARK gene encodes mRNA (GenBank accession number NM_030952) of seven exons. 
Northern blotting demonstrated that mRNA transcripts (at least two variants) for the 
SNARK were widely expressed in rodent tissues, but most abundant in rat kidney. Reverse-
transcriptase-mediated PCR detected two SNARK cDNA products in RNA from rat heart, 
skin, spleen, lung, uterus, liver and a neonatal rat keratinocyte cell line, NRKC. The two 
different SNARK PCR products were cloned, sequenced and found to encode either 
authentic SNARK (1437 bp) or an internally deleted SNARK transcript (1247 bp) [9]. 
Whereas rat kidney contained predominantly the intact SNARK transcript and testes 
expressed only the 1247 bp SNARK transcript, both intact and internally deleted SNARK 
transcripts were detected in other tested tissues. The ORF encodes a putative protein of 630 
amino acid residues with a predicted molecular mass of 70 kDa and a theoretical pI of 9.35. 
Translation of the SNARK-deleted transcript is predicted to give rise to a prematurely 
terminated protein of approximately 415 amino acid residues [9].  
Although no autophosphorylated products were detected in samples of immunoprecipitated 
endogenous SNARK from wild type BHK cells, one major phosphorylated band, possibly a 
protein doublet, was detected in the immunoprecipitates from SNARK-transfected BHK 
cells [9]. The size of the phosphorylated band(s) corresponds to the size of SNARK detected 
in these cell lines by Western blot analysis. Thus, these results demonstrate that SNARK is a 
protein kinase capable of autophosphorylation in vitro. Besides that, immunoprecipitated 
SNARK protein exhibits phosphotransferase activity with the synthetic peptide substrate 
HMRSAMSGLHLVKRR as a kinase substrate [9]. SNARK was translated in vitro to yield a 
single protein band of approximately 76 kDa, possibly a protein doublet, however, Western 
analysis of transfected BHK (baby hamster kidney) cells detected two SNARK-
immunoreactive bands of approximately 76 – 80 kDa.  
The NUAK family SNF1-like kinase 2 (NUAK2 or SNARK) is a member 4 of AMPK kinases 
which are related to serine/threonine protein kinases and contains all 11 catalytic 
subdomains conserved in these protein kinases. Analysis of the catalytic domain of SNARK 
with the Prosite program revealed a protein kinase ATP-binding region signature (residues 
63 – 89) and a serine/threonine protein kinase active-site signature (residues 175 – 187). The 
sequences at the C-terminus of SNARK were distinct and not well conserved with C-
terminal sequences of other SNF1/AMPK family members. The instability index is 
computed to be 58.40 with the Protparam Tool program, classifying protein kinase SNARK 
as an unstable protein [9]. 
Comparison of the SNARK catalytic subdomains I – XI to other SNF-1/AMPK family 
members demonstrates that protein kinase SNARK originated very early in eukaryotic 
evolution, diverging before the divergence of yeast and humans [9]. On the basis of the 
phylogeny of the catalytic subdomains, SNARK is no more closely related to SNF1 than it is 
to AMPK and represents a new branch of the SNF1/AMPK family of protein kinases. 
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2.2 Protein kinase SNARK, its activity and regulation 
The NUAK family SNF1-like kinase 2 is a member of AMPK kinases, it is commonly 
activated in response to cellular and environmental stresses, and it is a molecular 
component of the cellular stress response, but its precise mechanisms remain unclear [7, 9, 
11, 25]. Its activity is regulated by glucose- or glutamine-deprivation, induction of 
endoplasmic reticulum stress by homocysteine or dithiothreitol, hyperosmotic stress, salt 
stress, elevation of cellular AMP and/or depletion of ATP, ultraviolet B radiation and 
oxidative stress caused by hydrogen peroxide. However, the regulation of protein kinase 
SNARK activity in response to cellular stresses depends greatly upon cell type. Several 
aspects of SNARK activation and regulation are broadly similar to AMPK [8]. For example, 
SNARK and AMPK are both AMP-responsive and activated by treatments known to 
increase the AMP:ATP ratio, including glucose deprivation and chemical ATP production 
[9, 12]. Nevertheless, the metabolic role of SNARK at the cellular level, particularly in 
humans, especially in skeletal muscle, is incompletely resolved. 
Kuga et al. [12] identified the subcellular localization of SNARK protein. Unlike cytoplasmic 
localizing AMPK, SNARK was predominantly localized in the nucleus. This protein kinase 
is constitutively distributed in the nucleus; even when SNARK is activated by metabolic 
stimuli such as the AMP-mimetic agent, 5-aminoimidazole-4-carboxamide riboside (AICAR) 
or glucose-deprivation. Conserved nuclear localization signal was identified at the N-
terminal portion (68KKAR71) of protein kinase SNARK. Deletion and point mutation of this 
part resulted in the cytoplasmic translocation of mutant proteins. Furthermore, GFP fused 
with the SNARK fragment containing 68KKAR71 translocated to the nucleus.  
A microarray analysis revealed that nuclear localized SNARK alteres transcriptome profiles 
and a considerable part of these alterations were canceled by the mutation of nuclear 
localization signal (first two core lysine residues of 68KKAR71 were altered to alanine 
(68AAAR71)), suggesting the ability of SNARK to modulate gene expression is dependent on 
its nuclear localization. It has been shown that overexpression of protein kinase SNARK in 
human liver hepatoma cells results in the upregulation (more than 2.0-fold) of 76 mRNA 
targets and in the downregulation (more than 2.0-fold) of 32 mRNA targets, suggesting that 
this protein kinase can work as a stress-responsive transcriptional modulator in the nucleus 
[12].  
Moreover, transcriptome profiles of wild-type and nuclear localized signal-mutant SNARK 
expressing cells were compared to identify the impact of the nuclear localization of SNARK 
on the regulation of mRNA levels of potential downstream genes. Among the 76 up-
regulated probe sets by overexpressed SNARK, only eight probe sets increased more than 
2.0-fold in 68AAAR71-overexpressing cells compared with vector-transfected cells. On the 
other hand, among the 32 down-regulated probe sets by overexpressed SNARK, only 13 
probe sets decreased more than 2.0-fold in 68AAAR71-overexpressing cells compared with 
vector-transfected cells. Thus, overexpressed SNARK altered the gene expression profiles 
more than nuclear localization signal-mutant SNARK. This result implied that protein 
kinase SNARK in the nucleus, but not the cytoplasm, has a remarkable impact on gene 
expression and can work in the nucleus as a transcriptional modulator in response to stress. 
This data may become a platform to elucidate the molecular mechanism and the 
physiological signification of protein kinase SNARK.  
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AMPK and AMPK-related kinases are believed to be activated by increased AMP:ATP ratio 
through a direct activation mechanism of the allosteric effect and/or indirectly activated by 
phosphorylation at threonine residue in the activation loop by upstream kinases, LKB1 
(serine/threonine protein kinase 11, STK11), CaMKK (calcium/calmodulin-dependent 
protein kinase kinase 1, alpha), and TAK1 (mitogen-activated protein kinase kinase kinase 7; 
MAP3K7) [25]. CaMKK and TAK1 are localized in the cytoplasm, but LKB1 is localized in 
both nucleus and cytoplasm. Therefore SNARK might be phosphorylated in the nucleus by 
protein kinase LKB1 [12]. 
Rune et al. [11] showed that skeletal muscle SNARK expression is also regulated by 
metabolic stress and increases in human obesity, and in response to metabolic stressors. This 
increase in SNARK mRNA expression may occur as a consequence of systemic factors 
associated with metabolic impairments in obesity, since exposure of myotubes to elevated 
levels of TNF-α or palmitate acutely increased SNARK mRNA expression. siRNA against 
SNARK failed to rescue TNFα- or palmitate-induced insulin resistance, indicating that 
changes in SNARK expression occur as a consequence, rather than a cause of insulin 
resistance. Based on this data in human skeletal muscle, in the insulin-resistant and obesity 
phenotype in whole-body SNARK-haploinsufficient mice [13], SNARK expression in 
metabolically active tissues beyond skeletal muscle may play a role in whole body energy 
and glucose homeostasis. 
Interestingly, SNARK has anti-apoptotic properties, acting through a TNF-α-sensitive 
nuclear NF-κB-mediated mechanism. Thus, the SNF1/AMP kinase-related kinase 2, which 
is induced in response to various forms of metabolic stress, was identified as an NF-B-
regulated anti-apoptotic kinase that contributes to the tumour-promoting activity of death 
receptor CD95 (APO-1/Fas) in apoptosis-resistant tumour cells [26]. The death receptor 
CD95 induces apoptosis in many tissues. However, in apoptosis-resistant tumour cells, 
stimulation of CD95 induces up-regulation of a defined number of mostly anti-apoptotic 
genes, resulting in increased motility and invasiveness of tumour cells. The majority of these 
genes are known NF-B target genes. One of the CD95-regulated genes is the 
serine/threonine kinase (SNARK). It was shown that up-regulation of SNARK in response 
to CD95 ligand and tumour necrosis factor  depends on activation of NF-B. 
Overexpression of SNARK rendered tumour cells more resistant, whereas a kinase-inactive 
mutant of SNARK sensitizes cells to CD95-mediated apoptosis. Furthermore, small 
interfering RNA-mediated knockdown of SNARK increases the sensitivity of tumour cells to 
death receptor CD95 ligand- and TRAIL-induced apoptosis. Importantly, cells with reduced 
expression of SNARK also showed reduced motility and invasiveness in response to CD95 
engagement. SNARK therefore represents an NF-B-regulated anti-apoptotic gene that 
contributes to the tumour-promoting activity of CD95 in apoptosis-resistant tumour cells 
[26]. 
Kim et al. [27] have investigated the effect of Epstein-Barr virus (EBV) latent membrane 
protein 1 (LMP1) on human cancer cells for identification of potential target genes. It was 
found that LMP1 upregulated the expression of protein kinase SNARK compared with the 
empty vector transfected control cells. Moreover, SNARK expression increased drug 
resistance in response to doxorubicin, whereas knockdown of SNARK by siRNA effectively 
inhibited LMP-1-mediated increase of cell survival. SNARK stimulates the expression of 
anti-apoptotic genes BCL6 and BIRC2; knockdown of these genes decreased the SNARK-
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mediated increase of cell survival. These results suggest that SNARK is a downstream 
cellular target of LMP1 in malignant cells [27]. 
2.3 Protein kinase SNARK and tumourigenesis 
Members of the AMP kinase family play an important role in tumourigenesis [6]. This 
activity is believed to be due to their activation by various forms of metabolic stress such as 
glucose deprivation, a condition to be expected within solid tumours [28]. Recently, Namiki 
et al. [14] showed that AMP kinase-related kinase NUAK2 affects tumour growth, 
migration, and clinical outcome of human melanoma. This study further supports the 
importance of NUAK2 in cancer development and tumour progression, while AMPK has 
antioncogenic properties.  
Although several in vitro studies have suggested that metabolic stress as well as genotoxic or 
osmotic stresses induce SNARK activation, the physiological roles of protein kinase SNARK 
remain uncertain. Using SNARK-deficient mice helps to clarify the in vivo function of this 
kinase. Interestingly, SNARK(+/-) mice exhibited mature-onset obesity and related 
metabolic disorders [13]. Thus, an increased bodyweight in these mice is accompanied by fat 
deposition, fatty changes of the liver, and increased serum triglyceride concentration. These 
mice also exhibited hyperinsulinemia, hyperglycemia, and glucose intolerance, symptoms 
which are similar to those of human type II diabetes mellitus accompanied with obesity. 
Obesity is regarded as a risk factor for colorectal cancer. To investigate whether SNARK 
deficiency is involved in tumorigenesis in the large intestine, obese SNARK(+/-) mice were 
treated with a chemical carcinogen, azoxymethane, a chemical carcinogen that induces 
aberrant crypt foci, colorectal adenoma, and adenocarcinoma. The incidences of both 
adenomas and aberrant crypt foci were significantly higher in SNARK(+/-) mice than in 
their wild-type counterparts, suggesting that SNARK deficiency contributed to the early 
phase of tumourigenesis via obesity-dependent and -independent mechanisms [13]. 
2.4 Activation of protein kinase SNARK during muscle contraction 
Sakamoto  et al. [29] have shown that deficiency of LKB1 in skeletal muscle prevents AMPK 
activation and glucose uptake during contraction. In LKB1-lacking muscle, the basal activity 
of the AMPKalpha2 isoform was greatly reduced and was not increased by the AMP-
mimetic agent, 5-aminoimidazole-4-carboxamide riboside (AICAR), by the antidiabetic drug 
phenformin, or by muscle contraction. Moreover, phosphorylation of acetyl CoA carboxylase-
2, a downstream target of AMPK, was profoundly reduced. Glucose uptake stimulated by 
AICAR or muscle contraction, but not by insulin, was inhibited in the absence of LKB1. 
Contraction increased the AMP:ATP ratio to a greater extent in LKB1-deficient muscles than 
in LKB1-expressing muscles. These studies establish the importance of LKB1 in regulating 
AMPK activity and cellular energy levels in response to contraction and phenformin.  
Recently, Koh et al. [30] showed that muscle contraction also increases protein kinase 
SNARK activity and that this effect blunted in the muscle-specific LKB1 knockout mice. It is 
known that the signaling mechanisms that mediate the important effects of contraction, to 
increase glucose transport in skeletal muscle, occur through an insulin-independent 
mechanism. Moreover, muscle-specific knockout of protein kinase LKB1, an upstream 
kinase for AMPK and AMPK-related protein kinases, significantly inhibited contraction-
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stimulated glucose transport, suggests that one or more AMPK-related protein kinases are 
important for this process. It has been shown that expression of a mutant SNARK in mouse 
tibialis anterior muscle impaired contraction-stimulated, but not insulin-stimulated, glucose 
transport. The impaired contraction-stimulated glucose transport was also observed in 
skeletal muscle of whole-body SNARK heterozygotic knockout mice [30]. Thus, SNARK, the 
fourth member of the AMP-activated protein kinase catalytic subunit family, is activated by 
muscle contraction and is a unique mediator of contraction-stimulated glucose transport in 
skeletal muscle.  
There is data that NUAK2 is a TNFalpha-induced kinase which regulates myosin phosphatase 
target subunit 1 (MYPT1) activity by phosphorylation at a site other than known Rho-kinase 
phosphorylation sites (Thr696 or Thr853) responsible for inhibition of myosin phosphatase 
activity [31]. Moreover, Suzuki et al. [32] observed the induction of cell-cell detachment 
during glucose starvation through F-actin conversion by protein kinase SNARK. Recently, 
Vallenius et al. [33] have shown that an association between AMP kinase-related kinase 
SNARK and myosin phosphatase Rho-interacting protein (MRIP) reveals a novel 
mechanism for regulation of actin stress fibers via activation of MLCP (myosin light chain 
phosphatase). Moreover, new roles for the LKB1-NUAK pathway in controlling myosin 
phosphatase complexes and cell adhesion have been shown [34]. 
2.5 Protein kinase SNARK as a regulator of whole-body metabolism 
Ichinoseki-Sekine et al. [35] provide evidence for a robust effect on whole body metabolism 
by hemiallelic SNARK deficiency, suggesting that this AMPK-related kinase is a previously 
unrecognized important regulator of whole-body metabolism. They have investigated the in 
vivo effects of altering expression of SNARK by using hemiallelic loss of SNARK on whole 
body metabolic homeostasis and physical activity behaviour. Homozygous SNARK-
deficient mice have a high incidence of embryonic lethality, whereas the heterozygous 
SNARK-deficient mice have an obvious metabolic phenotype with mature-onset obesity and 
increased white adipose tissue mass evident after the age of 4 month.  
Activation of SNARK by upstream kinase LKB1 occurs by phosphorylation of Thr208, a 
conserved threonine residue equivalent in position to Thr172 within the activation loop of 
AMPKα2 [36]. LKB1 is attractive as a regulator of SNARK activity by virtue of its nuclear 
localization, which is coincident with the predominant nuclear localization of SNARK [12], 
but SNARK may also directly mediate some physiological effects of LKB1. Several aspects of 
SNARK regulation and activity are broadly similar to those of AMPK, which can be 
summarized as follows. First, SNARK possesses AMPK-like phosphotransferase activity; 
second, activation of SNARK is AMP responsive; third, SNARK activity is increased by 
AICAR, albeit in a cell-specific manner; and fourth, SNARK is activated by treatments 
known to increase AMP/ATP ratio or disrupt ATP production, including glucose 
deprivation and chemical ATP depletion among others [36].  
Possible AMPK activation of SNARK, secondary to the activation of AMPK by these 
treatments, has not been investigated but raises the possibility that one or more activities 
previously attributed to the AMPK-signaling cascade may be attributable, in part, to 
SNARK activation. In addition, similarities between AMPK and SNARK regulation do not 
necessarily infer that SNARK activity directly mirrors AMPK activity in the context of 
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cellular metabolism. Cell-specific differences are reported between SNARK and AMPK 
activity and pharmacological activation as well as in the relative rates of phosphorylation 
and peptide substrates phosphorylated [36]. 
Examining metabolic and anthropometric effects of SNARK deficiency, the core finding in 
Ichinoseki-Sekine et al. [35] investigation is that the provision of voluntary exercise 
opportunities to SNARK(+/-) mice results in habitually increased daily physical activity 
(∼2-fold) compared with SNARK(+/+) mice, commensurate with the prevention of mature-
onset obesity to which these animals are genetically predisposed. Physical activity resulted 
in a reduction in total body mass, liver mass, and white and brown adipose tissue mass in 
both exercise groups compared with sedentary controls. At termination of the study, body 
mass was similar between genotypes in the physically active mice. The prevention of weight 
gain in the active SNARK(+/-) mice occurred despite a 10% increase in food intake. 
Differences in physical activity were not attributable to sex, age, or disrupted circadian 
rhythm, nor were they attributable to any intrinsic deficit in forced exercise capacity/muscle 
energetic associated with SNARK deficiency. Direct SNARK-dependent modulation of 
whole body metabolism, similar to AMPK effects in the context of carbohydrate and lipid 
metabolism has not been demonstrated yet. However, SNARK is predominantly and 
constitutively localized in the nucleus, where it is likely to be regulated by protein kinase 
LKB1 or other unidentified kinases [12].  
Interestingly, the SNARK gene expression and kinase activity is tissue specific, and its 
activity profile differs significantly from the AMPKα2 activity profile. Therefore, targeting 
SNARK could potentially affect whole body metabolic homeostasis, and a more thorough 
examination of the physiological role of SNARK is warranted. Thus, protein kinase SNARK 
is a novel regulator of whole body metabolic homeostasis and highlights yet another protein 
kinase as an exciting new addition to the already extensive paradigm of homeostatic 
regulation by cellular energy sensors.  
2.6 Protein kinase SNARK and PFKFB-3 alternative splicing 
The new aspect of the biological role of protein kinase SNARK was demonstrated in 
SNARK-deficient mice by investigation of the expression of 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase-3 (PFKFB-3) mRNA and its alternative splice variants in 
the liver, lungs, testes, heart, and skeletal muscle [37]. Bifunctional enzyme PFKFB is a key 
regulatory enzyme of glycolysis which also participates in glucose phosphorylation [38, 39]. 
The PFKFB-3 expression significantly increased due to hypoxia in different normal and 
cancer cell lines via hypoxia inducible transcription factor (HIF)-dependent mechanism [40, 
41]. Hypoxia also induces expression of PFKFB-3 in different mouse organs in vivo, except 
skeletal muscle [42]. High expression level and phosphorylation status of PFKFB-3 as an 
important glycolytic regulator was determined in different malignant tumours [43–47]. 
Because SNARK deficiency contributed to the early phase of tumourigenesis and is important 
in cancer development and tumour progression [13, 14], investigation of the expression of 
PFKFB-3 and its alternative splice variants, which have different proliferative properties [48], 
is necessary for understanding the role of SNARK deficiency in tumourigenesis.  
As shown in Fig. 1, the expression levels of PFKFB-3 mRNA significantly increases in the 
liver and lung of SNARK(-/-) knockout mice as compared to corresponding tissues of 
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control C57BL/6 mice [37]. At the same time, PFKFB-3 mRNA expression level in skeletal 
muscle of SNARK knockout mice decreases without significant changes in the heart as 
compared to control animals. Thus, SNARK deficiency leads to variable changes of PFKFB-3 
mRNA expression in different mouse tissues.  
Reverse-transcriptase-mediated PCR of the carboxyl-terminus of PFKFB-3 mRNA detected 
three – four cDNA products in RNA from the liver, lung, testis, heart, and skeletal muscle of 
control C57BL/6 and SNARK knockout mice (Fig. 2). This heterogeneity is a result of 
alternative splicing of the PFKFB-3 mRNA in tissue specific manner. Alternative splice 
variants of PFKFB-3 mRNA were identified by sequence analysis of cloned fragments. The 
major difference among the members of these bifunctional enzyme alternative splice 
variants is the length and composition of the carboxyl-terminal region (Fig. 3 and 4), 
supporting the idea that this terminus of the various enzyme isoforms serve to adapt the 
kinetic properties of the catalytic core to metabolic exigencies of a particular tissue. 
Alternative splice variants of PFKFB-3 also have different amounts and sequence positions 
of serine residues which are very important in the regulation of isozyme activity via 
phosphorylation [39, 46]. It was shown that the pattern of alternative splice variants of the 
PFKFB-3 mRNA differs in different mouse organs (Fig. 2). 
Results of this study strongly support the SNARK dependent regulation of PFKFB 
alternative splicing. Thus, the level of smallest alternative splice variant increases in the 
heart and liver of SNARK knockout mice compared with control mice. However, the level of 
longest alternative splice variant decreases in the skeletal muscle of SNARK knockout mice 
compared with control mice (Fig, 2). Therefore, investigation of different alternative splice 
variants of PFBFB-3 isozymes is important for comprehension of tissue-specific regulation 
mechanisms of glycolysis. The precise molecular mechanisms, whereby SNARK participates 
in the splicing of PFKFB as well as a role of different isoenzymes in the regulation of 
glycolysis, await further study. 
 
Fig. 1. Real time PCR analysis of PFKFB-3 mRNA expression in liver, lung, heart and 
skeletal muscle of control C57BL/6 male mice (C) and SNARK(-/-) knockout mice (KO). 
Amplification of PFKFB-3 mRNA was carried out using M4 forward and M5 reverse 
primers. Intensities of PFKFB-3 mRNA expression were normalized to -actin mRNA [37]. 
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Fig. 2. RT-PCR analysis of PFKFB-3 mRNA expression in the heart, liver, lung, testis and 
skeletal muscle of control C57BL/6 (+/+) and SNARK knockout mice (-/-). Amplification of 
PFKFB-3 mRNA was carried out using M3 forward and M6 reverse primers. The amplified 
PCR products were run on an agarose gel. Intensities of PFKFB-3 mRNA bands were 
normalized to -actin mRNA [37]. 
 
Fig. 3. Schematic representation of exon structure of mouse PFKFB-3 mRNA alternative 
splice variants. Most of these splice variants do not have exon 13th. Some of splice variants 
have 15th and 15tha exons which alters the reading frame, amino acid sequence and length of 
C-terminus. One splice variant is shortest because it does not have exon 14th. Position of 
three possible stop codons for the different alternative splice variants of PFKFB-3 mRNA are 
shown by asterisk. The GenBank accession number of alternative splice variants of mouse 
PFKFB-3 is noted on the left [38]. 
2.7 SNARK kinase as a stress sensor and sensitive marker of silver nanoparticles and 
methyl tert-butyl ether action  
Recently we have shown that the expression of SNF1/AMP-activated protein kinase 
(SNARK) increases in different organs of male Wistar rats intratracheally instilled by 30% 
silver nanoparticles (28-30 nm) in sodium chloride matrix aerosol in dose 50 g/kg (or  0.05 
mg/kg) body weight (=15 g of silver) [15]. Silver nanoparticles were prepared in the 
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Laboratory No. 84 of the Paton Electric Welding Institute of The National Academy of 
Sciences of Ukraine. The expression levels of the SNARK mRNA were analyzed in the lung, 
liver, brain, heart, kidney and testis using quantitative polymerase chain reaction on the 1st, 
3rd or 14th day after one-time intratracheally treated rats with silver nanoparticles. 
 
Fig. 4. Amino acid sequence of alternative splice variants of mouse PFKFB-3. Differences in 
amino acid sequences and length of C-terminus of different alternative splice variants of 
mouse PFKFB-3 are shown. Serine residues are underlined. The GenBank accession number 
of alternative splice variants of mouse PFKFB-3 is noted on the left [38]. 
It was shown that the expression of protein kinase SNARK mRNA increases in the liver, 
lung and brain on the 1st, 3rd and 14th day after one-time treatment of rats with silver 
nanoparticles, being more intense (more than 2 fold) on the 3rd and 14th day in the brain and 
liver and on the 1st day in the lung (Fig. 5 and 6). Results of Fig. 6 and 7 also indicated that 
SNARK mRNA expression does not change significantly in the heart and testes on the 1st  
 
Fig. 5. The effect of silver nanoparticles on the expression of protein kinase SNARK mRNA in 
the liver and lung in 1, 3 or 14 days (d) after treatment. Values of SNARK mRNA expressions 
were normalized to -actin mRNA expression; C – control; n = 3; * - P < 0.05 [15]. 
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Fig. 6. The effect of silver nanoparticles on the expression of protein kinase SNARK mRNA 
in the brain and testis in 1, 3 or 14 days (d) after treatment. Values of SNARK mRNA 
expressions were normalized to -actin mRNA expression; C – control; n = 3; * - P < 0.05 
[15]. 
and 14th days after treatment of rats with silver nanoparticles, but there is a clear increase of 
SNARK expression on the 3rd day as compared to control animals. Results of Fig. 7 show 
that SNARK mRNA expression also increases in the kidney on the 1st, 3rd and 14th day after 
treatment of rats with silver nanoparticles, being more intense on the 3rd and 14th days; 
however, this induction is significantly less when compared to the liver, lung or brain.  
Thus, one-time intratracheally instilled silver nanoparticles change the expression of the 
protein kinase SNARK in different rat organs, not only in the lung tissue. Moreover, this 
effect of silver nanoparticles on the expression of the protein kinase SNARK strongly 
depends on time after the treatment of rats with these nanoparticles in a tissue-specific 
manner. These results correlate to data from Lefebvre and Rosen [7] whom have shown that 
the regulation of protein kinase SNARK activity in response to cellular stresses greatly 
depends upon cell type.  
 
Fig. 7. The effect of silver nanoparticles on the expression of protein kinase SNARK mRNA in 
the kidney and heart in 1, 3 or 14 days (d) after treatment. Values of SNARK mRNA 
expressions were normalized to -actin mRNA expression; C – control; n = 3; * - P < 0.05 [15]. 
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Shimada et al. [49] demonstrated that the intratracheally instilled ultrafine nanoparticles are 
able to translocate from the mouse lung into systemic circulation. Precise mechanisms of the 
anatomical translocation (crossing the air-blood barrier) of inhaled nanoparticles at the 
alveolar wall are not fully understood. Silver nanoparticles are widely used in the field of 
biomedicine, but a comprehensive understanding of how silver nanoparticles distribute in 
the body and the induced toxicity remains largely unknown. Tang et al. [50] investigated the 
distribution and accumulation of silver nanoparticles in rats with subcutaneous injection. 
Rats were injected with either silver nanoparticles SNPs or silver microparticles (SMPs) at 
62.8 mg/kg, and then sacrificed at predetermined time points. Silver content analysis by 
Inductively coupled plasma mass spectrometry was used for determination of silver content 
in different organs. Results indicated that silver nanoparticles translocated into the blood 
circulation and distributed throughout the main organs, especially in the kidney, liver, 
spleen, brain and lung in the form of particles. Ultrastructural observations indicate that 
those silver nanoparticles that had accumulated in organs could enter different kinds of 
cells. Moreover, silver nanoparticles also induced blood-brain barrier (BBB) destruction and 
astrocyte swelling, and caused neuronal degeneration [50].  
There is data that silver nanoparticles are more toxic than silver microparticles or ions [51–
53]. Powers et al. [53] have shown that silver nanoparticles have the potential to evoke 
developmental neurotoxicity even more potently than known neurotoxicants. Silver ions 
inhibited replication and increased cell death in undifferentiated cells, and selectively 
impaired neurite formation. Silver nanoparticles in D. melanogaster induce heat shock 
stress, oxidative stress, DNA damage and apoptosis [54]. Thus, silver nanoparticles up-
regulate the expression of heat shock protein 70, the cell cycle checkpoint p53 and cell 
signaling protein p38 all of which are involved in the DNA damage repair pathway. 
Moreover, the activity of caspase-3 and caspase-9, markers of apoptosis was significantly 
higher in silver nanoparticles exposed organisms. 
It is possible that silver nanoparticles create stress conditions which affect the expression of 
protein kinase SNARK mRNA via unfolded protein response signals through activation of 
inositol requiring enzyme-1 (endoplasmic reticulum–nuclei-1) and alternative splicing of 
XBP-1 [55 – 57]. Endoplasmic reticulum stress signalling activates inositol requiring enzyme-
1 and XBP-1 which control diverse cell type- and condition-specific transcriptional 
regulatory networks. However, the cellular mechanism for survival under stress conditions 
is complex and further investigation of the mechanism by which silver nanoparticles affects 
protein kinase SNARK expression as well as biologic significance of silver nanoparticles 
induced alteration in the expression of these genes is needed. The stage is now set for the 
elucidation of the molecular mechanisms responsible for these important SNARK responses 
to silver nanoparticles action.  
Results of investigations clearly demonstrate that silver nanoparticles have a significant 
effect on important regulatory mechanisms which control metabolic processes in different 
tissues via SNARK gene expression, which can be considered as a sensitive marker for silver 
nanoparticles action. These results suggest that more caution is needed in biomedical 
applications of silver nanoparticles as well as higher level of safety in the silver 
nanoparticles production industry. 
We have also studied the effect of different doses of ecotoxicant methyl tertbutyl ether on 
the expression protein kinase SNARK in the liver, lung and heart [16]. Results of this 
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investigation demonstrated that methyl tertbutyl ether affects the expression protein kinase 
SNARK in the liver, lung and heart in dose dependent and tissue specific manner and that 
very small dose induce the expression of protein kinase SNARK in all tested vital organs in 
rats (Fig. 8 and 9). There is data that methyl tertbutyl ether can initiate the variety of 
neurotoxic, allergic and respiratory illnesses, liver hypertrophy and leukaemia in humans as 
well as the following cancers in rats and mice: kidney, liver, testicular and lymph nodes, 
initiate development of leukemia [58, 59]. We have recently shown that methyl tertbutyl 
ether affects the expression of PFKFB-4 mRNA and its alternative splicing [60]. Thus, 
SNARK gene expression can be considered as sensitive markers for the methyl tertbutyl 
ether action. 
 
Fig. 8. Effect of methyl tertbutyl ether [0.5 (M 0,5); 5 (M 5); 50 (M 50) та 500 (M 500) mg/kg 
body weight during two months] on SNARK mRNA expression in the liver, lung and heart 
by reverse-transcriptase-mediated PCR. C – control rats. 
 
Fig. 9. Effect of methyl tertbutyl ether [0.5 (M 0,5); 5 (M 5); 50 (M 50) та 500 (M 500) mg/kg 
body weight during two months] on the expression levels of SNARK mRNA in the liver, 
lung and heart by quantitative PCR. C – control rats. 
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3. SNF1-like kinase, 1 (NUAK1) AMP-activated protein kinase family member 
5, ARK5 
Human NUAK family SNF1-like kinase 1 (NUAK1; EC_number "2.7.11.1") is an 
AMP-activated protein kinase family member, ARK5. AMP-activated protein 
kinases (AMPKs) are a class of serine/threonine protein kinases that are activated 
by an increase in intracellular AMP concentration. They are a sensitive indicator of 
cellular energy status and have been found to promote tumor cell survival during 
nutrient starvation. The human gene encoded protein kinase NUAK1 (ARK5) is 
located on chromosome 12 ("12q23.3"; GeneID: 9891). This gene encodes a protein 
of 661 amino acid residues. ARK5, which is the fifth member of the AMPK catalytic 
subunit family, is a tumor malignancy-associated factor at the downstream of Akt 
[19]. ARK5 is a tumour cell survival and invasion-associated factor. The activated 
ARK5 induces cell survival during nutrient starvation and death receptor 
activation, and tumor cell invasion and metastasis [18–21]. 
However, the precise mechanisms of how ARK5 activity inhibits caspase dependent cell 
death remains to be determined. Both cell death and cell survival are important for cellular 
homeostasis; therefore, an imbalance of their signalling causes several disease states, 
including tumourogenesis.  
ARK5, as an AMP-activated protein kinase family member 5, is a tumour progression-
associated factor that is directly phosphorylated by AKT at serine 600 in the regulatory 
domain, but phosphorylation at the conserved threonine residue on the active T loop has 
been found to be required for its full activation [18, 19]. Suzuki et al. [61] identified 
serine/threonine protein kinase NDR2 as a protein kinase that also phosphorylates and 
activates ARK5 during insulin-like growth factor-1 (IGF-1) signalling. Upon stimulation 
with IGF-1, protein kinase NDR2 was found to directly phosphorylate the conserved 
threonine 211 on the active T loop of protein kinase ARK5 and to promote cell survival and 
invasion of colorectal cancer cell lines through ARK5.  
During IGF-1 signaling, phosphorylation at three residues (threonine 75, serine 282 and 
threonine 442) was also found to be required for NDR2 activation. Among these three 
residues, phosphorylation of serine 282 seemed to be most important for NDR2 activation 
(the same as for the mouse homologue) because its aspartic acid-converted mutant 
(NDR2/S282D) induced ARK5-mediated cell survival and invasion activities even in the 
absence of IGF-1. Threonine 75 in protein kinase NDR2 was required for interaction with 
protein S100B, and binding was in a calcium ion-dependent and phospholipase C-gamma-
dependent manner [61]. Thus, protein kinase NDR2 is an upstream kinase of ARK5 that 
plays an essential role in tumour progression through an AMP-activated protein kinase 
ARK5. 
NUAK1 acts as an ATM kinase under the conditions of nutrient starvation and plays a key 
role in tumour malignancy downstream of Akt signalling [19]. Matrigel invasion assays 
demonstrated that both overexpressed and endogenous ARK5 showed strong Akt 
dependent activity. In addition, ARK5 expression induced activation of matrix 
metalloproteinase 2 (MMP-2) and MMP-9. In nude mice, ARK5 expression was associated 
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with a significant increase in tumour growth and significant suppression of necrosis in 
tumour tissue. Interestingly, only the ARK5-overexpressing PANC-1 cell line tumour 
showed invasion and metastasis in nude mice, although Akt was activated in tumours 
derived from both PANC-1 and ARK5-overexpressing PANC-1 cell lines. 
Suzuki et al. [21] have investigated the mechanisms of induction of cell survival by protein 
kinase ARK5 and have shown that ARK5 suppresses the apoptosis induced by nutrient 
starvation and death receptors via inhibition of caspase 8 activation. Thus, human hepatoma 
HepG2 cells undergo necrotic cell death within 24 h after the start of glucose starvation, and 
the cell death signaling has been found to be mediated by death-receptor-independent 
activation of caspase 8. When HepG2 cells were transfected with ARK5 expression vector 
and subjected to several cell death stimuli, ARK5 was found to suppress cell death by 
glucose starvation and TNF-alpha, but not by camptothecin or doxorubicin. Western 
blotting analysis revealed that glucose starvation induced Bid cleavage and FLIP 
degradation following caspase 8 activation in a time-dependent manner, and ARK5 
overexpression clearly delayed Bid cleavage, FLIP degradation, and caspase 8 activation. 
These results demonstrated that cell survival induced by ARK5 is, at least in part, due to 
inhibition of caspase 8 activation. 
AMP-activated protein kinase family member 5 also negatively regulates procaspase-6 by 
phosphorylation at serine 257, leading to resistance to the FasL/Fas system the key 
regulator promoting cell death and cell survival [22]. Fas is a type I transmembrane protein 
mediating intracellular cell death signalling upon the stimulation of Fas ligand (FasL). When 
Fas is activated by the ligation of FasL, an intracellular interaction of Fas death domain (Fas-
DD), FADD, and caspase-8 (death inducing signalling complex (DISC) recruitment) is 
initiated for the activation of executioner caspase; and cellular FLIP is well known as the 
inhibitor of DISC recruitment. The serine/threonine protein kinase Akt induces cell survival 
as a result of phosphorylation and several cell death-associated factors, such as Bad, 
caspase-9 and Forkhead, upon the stimulation of growth factor receptor and integrin-
induced cell signaling. Although active caspase-6 overexpression induced cell death in 
SW480 and DLD-1 cell lines, SW480 cells, but not DLD-1 cells, exhibite strong resistance to 
procaspase-6 overexpression. Moreover, mutant caspase-6, in which the serine 257 was 
substituted by alanine (caspase-6/SA), induced cell death and FLIP degradation, even in 
SW480 cells. Active ARK5 was found to phosphorylate wild-type caspase-6 in vitro, but not 
caspase-6/SA, and the prevented activation of caspase-6 was promoted due to its 
phosphorylation by active ARK5 in vitro.  
AMPK-related kinases NUAK1 and many others (including MARK/PAR-1) are regulated 
by protein kinase LKB1 and USP9X [23, 24]. Moreover, there is data that the LKB1-NUAK 
pathway plays important role in controlling myosin phosphatase complexes and cell 
adhesion [34]. NUAK1 regulates ploidy and senescence; cells that constitutively express 
NUAK1 suffer gross aneuploidies and show diminished expression of the genomic stability 
regulator LATS1, whereas depletion of NUAK1 with shRNA exerts opposite effects [17].  
AMP-activated protein kinase-related kinase 5 (ARK5/NUAK1) is expressed in rat skeletal 
muscle and phosphorylated by electrically elicited contractions and 5-aminoimidazole-4-
carboxamide-1-beta-d-ribofuranoside (AICAR). Increased phosphorylation of ARK5 by 
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muscle contractions or exposure to AICAR, however, is insufficient to activate this protein 
kinase in skeletal muscle, suggesting that some other modification (e.g., phosphorylation on 
tyrosine or by Akt) may be necessary for its activity in muscle [62]. 
4. Conclusions 
NUAK family SNF1-like kinase includes two kinases, NUAK1 and NUAK2; both are 
members of AMP-activated protein kinases which are related to serine/threonine protein 
kinases. The sucrose-non-fermenting protein kinase (SNF1)/AMP-activated protein kinase-
related kinase (SNF1/AMP-activated protein kinase; SNARK) is a member 4 of AMPK 
kinases (NUAK family SNF1-like kinase 2; NUAK2). SNF1-like kinase 1 (NUAK1) is an 
AMP-activated protein kinase family member 5, ARK5. Protein kinase NUAK2 (SNARK) is 
a molecular component of the cellular stress response and an important regulator of whole-
body metabolism. Protein kinase SNARK was consistently localized in the nuclei. It has 
been shown that the nuclear localizing SNARK alters transcriptome profiles. It therefore 
represents a NF-B-regulated anti-apoptotic gene that contributes to the tumour-promoting 
activity of death receptor CD95 in apoptosis-resistant tumour cells and plays an important 
role in cancer development and tumour progression. SNARK affects tumour growth, 
migration, and clinical outcome of human melanoma. Protein kinase SNARK is also 
activated by muscle contraction and is a unique mediator of contraction-stimulated glucose 
transport in skeletal muscle. Moreover, association between AMP kinase-related kinase 
SNARK and myosin phosphatase Rho-interacting protein reveals a novel mechanism for 
regulation of actin stress fibers via activation of myosin light chain phosphatase. Protein 
kinase NUAK1 (ARK5) regulates ploidy and senescence, tumour cell survival, malignancy 
and invasion downstream of Akt signalling and suppresses apoptosis induced by nutrient 
starvation and death receptors via inhibition of caspase-8 and caspase-6 activation. It is 
interesting to note that the expression of SNARK is a sensitive marker of silver nanoparticles 
and methyl tert-butyl ether toxic effect.  
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